Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
etherna logo — Enabling Nucleic Acid Medicines for Next‑Generation Therapie...

etherna

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be

Founded 2013 Belgium Belgium 97 employees Series B Total: $104.90M Biotechnology, Health Care +2

General Information

Company Name etherna
Founded Year 2013
Location Belgium Belgium
Founders / Decision Makers
Team member
Employees 97
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series B
Business Model B2B, B2B2B, Platform
Revenue Model Service Fee, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with etherna. To contact etherna, visit etherna.be.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does etherna compare?

A PDF of etherna and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting etherna soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About etherna

etherna, founded in 2013, is a pioneering company in the domain of nucleic acid–based medicine technology, headquartered in Belgium. The company operates a platform that addresses the intricate challenges of RNA chemistry and LNP formulation, effectively supporting both emerging and established players in the pharma and biotech industries.

The expertise of etherna in driving discovery and resolving manufacturing complications positions it as an essential partner for biotech firms developing next-generation therapies. This strategic alignment is underscored by their slogan, "Enabling Nucleic Acid Medicines for Next‑Generation Therapies."

In recent times, etherna secured a substantial €39.00M Series B investment on 01 August 2022, supported by notable investors such as Kennet Partners, FunPlus Ventures, Novalis LifeSciences, Omega Funds, PMV, and China Grand Pharmaceutical and Healthcare Holdings, along with EQT Life Sciences. This financial backing reflects strong confidence in their capacity to advance pivotal healthcare solutions.

Business keywords: Nucleic Acid Medicines, RNA Chemistry, LNP Formulation, Nucleic Acid Therapeutics, mRNA Production, Drug Product Production, Process Technologies, GMP mRNA, mRNA Therapies, Biotech Partnerships, Pharma Collaborations, Pipeline Development, Manufacturing Solutions, Technology Platform, Nucleic Acid-Based Drug Development

Services & Products

LNP platforms development
mRNA platforms development
RNA chemistry expertise
Technology partnering
Product partnering
Pipeline development
Manufacturing solutions

Target Customers

Pharmaceutical companies Biotech companies Start-up projects Early-stage projects Late-stage projects

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €39.00M 7
Kennet Partners FunPlus Ventures Novalis LifeSciences
Kennet Partners, FunPlus Ventures +5
01 Aug 2022
Grant €6.90M 1
European Commission
01 Mar 2021
Series B €34.00M 8
BNP Paribas Fortis Boehringer Ingelheim FunPlus Ventures
BNP Paribas Fortis, Boehringer Ingelheim +6
01 Jun 2020
Grant €1.00M 2
IWT
IWT, The Institute for the Promotion of Innovation by Science and Technology in Flanders
01 Sep 2017
Series A €24.00M 3
PMV
PMV, EQT Life Sciences +1
01 Mar 2016
Spinout Undisclosed 1
Vrije Universiteit Brussel
01 Jan 2013

etherna Alternatives & Competitors

View All Alternatives
etherna vs
Arcturus Therapeutics
Arcturus Therapeutics United States

A messenger RNA medicines company focused on the development of liver and respiratory rare disease t...

Grant
155 employees
Biotechnology, Health Care
Compare etherna vs Arcturus Therapeutics
etherna vs
Gennao Bio
Gennao Bio United States

A genetic medicines company developing first-in-class, targeted nucleic acid therapeutics

Series A
5 employees
Biotechnology, Health Care
Compare etherna vs Gennao Bio
etherna vs
leon-nanodrugs
leon-nanodrugs Germany

THE FUTURE OF NANOPARTICLE MANUFACTURING

Series B
20 employees
Biotechnology, Health Care
View all alternatives

FAQ About etherna

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be
etherna was founded in 2013.
etherna is headquartered in Belgium.
etherna operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on Nucleic Acid Medicines, RNA Chemistry, LNP Formulation and Nucleic Acid Therapeutics. Its customers include Pharmaceutical companies, Biotech companies and Start-up projects.
etherna has a B2B, B2B2B and Platform business model. Its revenue comes from Service Fee, Licensing and Project Based.
etherna has approximately 97 employees.
etherna has completed 6 funding rounds, raising a total of $104.90M. The latest funding stage is Series B.
etherna offers: LNP platforms development, mRNA platforms development, RNA chemistry expertise, Technology partnering, Product partnering, Pipeline development, Manufacturing solutions.
Top alternatives and competitors to etherna include Arcturus Therapeutics, Gennao Bio, leon-nanodrugs, 环码, Nuntius Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
etherna and Arcturus Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for etherna, https://bouncewatch.com/company/etherna, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout